Tonix Pharmaceuticals Holding Corp.

TNXP

Healthcare|Biotechnology|US

$4.74

+0.14 (+3.04%)

DCF Value

$24.35

Tangible Book / Share

$13.35

Cash / Share

$10.59

Financing Filings (last 12 months)

Shelf registrations / offering prospectuses — latest Dec 29, 2025 (424B5). Possible dilution.

Upcoming Data Readouts (3)

Jun 2027

Est. completion

P1Vasopressin Deficiency

Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency

NCT04789148n=40

Feb 2028

Est. completion

P2Major Depressive Episode (MDE)

A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

NCT07621237n=360

Nov 2028

Est. completion

P2Pain

Evaluating Intranasal Oxytocin (TNX-1900) for Pain Relief and Recovery After Pituitary Surgery

NCT07730294n=75

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Feb 2026

A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants

NCT07413367

Recent Press Releases

Tonix Pharmaceuticals to Present at Guggenheim's 3rd Annual Healthcare Innovation Conference

Nov 4, 2026 · GlobeNewsWire

Tonix Pharmaceuticals Appoints George Lederman, Ph.D., as Executive Vice President of Strategy and Transformation

Nov 2, 2026 · GlobeNewsWire

Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain

Oct 27, 2026 · GlobeNewsWire

Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026

Oct 26, 2026 · GlobeNewsWire

Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain

Oct 19, 2026 · GlobeNewsWire

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026

Oct 15, 2026 · GlobeNewsWire

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

Sep 22, 2026 · GlobeNewsWire

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

Sep 8, 2026 · GlobeNewsWire

Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference

Sep 2, 2026 · GlobeNewsWire

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Aug 10, 2026 · GlobeNewsWire

SEC Filings (122)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

Filed	Form	What it is	Links
Oct 15, 2026	8-K	Material event	Document Index
Oct 2, 2026	8-K	Material event	Document Index
Sep 22, 2026	8-K	Material event	Document Index
Sep 8, 2026	8-K	Material event	Document Index
Aug 18, 2026	8-K	Material event	Document Index
Aug 14, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Aug 13, 2026	SC 13G	Passive 5%+ stake	Document Index
Aug 10, 2026	10-Q	Quarterly report	Document Index
Aug 10, 2026	8-K	Material event	Document Index
Aug 3, 2026	8-K	Material event	Document Index
Jul 21, 2026	8-K	Material event	Document Index
Jul 13, 2026	8-K	Material event	Document Index
Jul 1, 2026	S-8	Employee stock plan	Document Index
Jun 29, 2026	8-K	Material event	Document Index
Jun 15, 2026	SC 13G	Passive 5%+ stake	Document Index
Jun 8, 2026	8-K	Material event	Document Index
May 27, 2026	8-K	Material event	Document Index
May 15, 2026	SC 13G/A	Passive 5%+ stake	Document Index
May 15, 2026	8-K	Material event	Document Index
May 15, 2026	SC 13G	Passive 5%+ stake	Document Index
May 11, 2026	8-K	Material event	Document Index
May 11, 2026	10-Q	Quarterly report	Document Index
May 7, 2026	8-K	Material event	Document Index
May 6, 2026	8-K	Material event	Document Index
May 1, 2026	8-K	Material event	Document Index
Apr 29, 2026	8-K	Material event	Document Index
Apr 23, 2026	8-K	Material event	Document Index
Mar 31, 2026	8-K	Material event	Document Index
Mar 30, 2026	DEF 14A	Proxy / shareholder vote	Document Index
Mar 27, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Mar 26, 2026	8-K	Material event	Document Index
Mar 20, 2026	PRE 14A	Proxy / shareholder vote	Document Index
Mar 18, 2026	8-K	Material event	Document Index
Mar 13, 2026	ARS	Annual report to holders	Document Index
Mar 13, 2026	8-K	Material event	Document Index
Mar 12, 2026	10-K	Annual report	Document Index
Mar 10, 2026	8-K	Material event	Document Index
Mar 3, 2026	8-K	Material event	Document Index
Feb 3, 2026	8-K	Material event	Document Index
Jan 30, 2026	SC 13G/A	Passive 5%+ stake	Document Index